後藤康洋

ゴトウヤスヒロ (goto yasuhiro)

基本情報

所属: 藤田医科大学呼吸器内科学准教授

学位: 医学博士(2010年1月名古屋大学)

連絡先: gotoyasufujita-hu.ac.jp
J-GLOBAL ID: 201501020248290142
researchmap会員ID: 7000012732

研究分野

ライフサイエンス / 呼吸器内科学 /

経歴

2025年8月 - 現在

藤田医科大学呼吸器内科学准教授
2018年7月 - 2025年7月

藤田保健衛生大学呼吸器内科学I講座講師
2014年4月 - 2018年6月

藤田保健衛生大学呼吸器内科学I講座講師（定員外）
2009年6月 - 2014年3月

名古屋掖済会病院呼吸器科医長
2008年4月 - 2009年5月

名古屋掖済会病院呼吸器科医員

もっとみる

学歴

2004年4月 - 2008年3月

名古屋大学大学院医学系研究科呼吸器内科学講座
1993年4月 - 1999年3月

名古屋大学医学部医学科

委員歴

2022年4月 - 現在

日本呼吸器学会教育委員会
2022年4月 - 現在

日本呼吸器学会肺移植検討委員会
2019年3月 - 現在

中日本呼吸器臨床研究機構（CJLSG) 理事
2018年4月 - 現在

名古屋市公害健康被害認定審査会委員
2019年4月 - 2022年3月

一般社団法人日本静脈経腸栄養学会肺疾患ワーキングチーム

論文

251

Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer

Masaki Ishida, Tadaaki Yamada, Yasuhiro Goto, Taiichiro Otsuki, Hirokazu Taniguchi, Taishi Harada, Akihiro Yoshimura, Shinsuke Shiotsu, Asuka Okada, Kazuki Jinno, Hibiki Kanda, Noeru Inoguchi, Mototaka Fukui, Takahiro Yamada, Tae Hata, Hayato Kawachi, Yuki Katayama, Kenji Morimoto, Masahiro Iwasaku, Takashi Kijima, Koichi Takayama

ISCIENCE 29(6) 2026年6月19日
Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Yasuhiro Goto, Sayaka Uda, Akira Nakao, Shinsuke Shiotsu, Yuji Kukida, Keiko Tanimura, Akifumi Miyamoto, Yuki Imasato, Asuka Okada, Isao Hasegawa, Koji Date, Yohei Matsui, Shoki Morito, Noeru Inokuchi, Shuji Osugi, Hayato Kawachi, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Tomohiro Handa, Koichi Takayama

Respiratory investigation 64(4) 101463-101463 2026年6月5日

BACKGROUND: Nintedanib is widely used for idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD). However, real-world data regarding its efficacy and safety in patients aged 75 years or older remain limited. This study aimed to evaluate these parameters in an older Japanese population. METHODS: We retrospectively enrolled patients who initiated nintedanib for IPF or PF-ILD between August 2019 and July 2023 across 15 institutions. Patients were stratified into the older group (≥75 years) and the younger group (<75 years). Clinical outcomes, including annual forced vital capacity (FVC) decline and the incidence of adverse events, were compared. RESULTS: The older and younger groups comprised 191 and 222 patients, respectively. The median survival time after nintedanib initiation was significantly shorter in the older group (1054 vs. 1400 days). The annual FVC change after nintedanib initiation was -61.3 and -61.4 mL/year for the younger and older groups, respectively. Although older patients frequently required dose reductions or had shorter treatment durations, the overall adverse events incidence remained similar (65.4% in the older group vs. 68.9% in the younger group). No significant differences were observed in the time to adverse events onset or severity. CONCLUSIONS: In real-world clinical practice, nintedanib demonstrated comparable efficacy in attenuating pulmonary function decline and a similar safety profile in older patients compared to younger patients. The shorter survival in older patients likely reflects diminished physiological reserve against respiratory events rather than reduced therapeutic efficacy. These findings support nintedanib use for interstitial lung disease in older populations.
Efficacy and safety of anamorelin in patients with non-small cell lung cancer and cancer cachexia undergoing chemoimmunotherapy: A real-world prospective cohort study (SPIRAL-ANA).

Kenji Morimoto, Junji Uchino, Makoto Hibino, Yuki Takeyasu, Ken Yamamoto, Yoshie Morimoto, Yusuke Chihara, Takayuki Nakano, Hiroyasu Kaneda, Shunya Tanaka, Shinsuke Ogusu, Yasuhiro Goto, Takayuki Shimose, Koichi Takayama

JOURNAL OF CLINICAL ONCOLOGY 44(16_SUPPL) 2026年6月1日
Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.

Shiho Goda, Tadaaki Yamada, Yasuhiro Goto, Sayaka Uda, Akira Nakao, Shinsuke Shiotsu, Yuji Kukida, Keiko Tanimura, Akifumi Miyamoto, Yuki Imasato, Asuka Okada, Isao Hasegawa, Koji Date, Yohei Matsui, Shoki Morito, Noeru Inokuchi, Shuji Osugi, Hayato Kawachi, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Tomohiro Handa, Koichi Takayama

BMC pulmonary medicine 2026年5月19日

BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation, with prognostic value in interstitial lung disease (ILD). However, the association between baseline NLR and the therapeutic efficacy of nintedanib remains unclear. This study investigates the relationship between baseline NLR values and clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF) and progressive fibrosing-ILD (non-IPF ILD) receiving nintedanib therapy. METHODS: This retrospective multicenter study included 406 patients-169 with IPF and 237 with non-IPF ILD-who initiated nintedanib treatment between 2019 and 2023 across 15 institutions in Japan. Patients were stratified into low- and high-NLR groups using a cutoff of 2.86. Comparative analysis assessed survival time, forced vital capacity (FVC) changes, and acute exacerbations. RESULTS: The high-NLR group demonstrated shorter median survival time in the overall study population (1,171 vs. 1,386 days; p =0.025). In subgroup analyses, higher NLRs were associated with shorter survival time in patients with IPF (778 vs. 1,447 days; p =0.006), but not in the non-IPF ILD group. While nintedanib mitigated FVC decline in most subgroups, this effect was attenuated in patients with IPF and high-NLR, with no statistically significant benefit (-8.63% vs. -6.71%). In multivariable analysis, NLR was not found to be an independent predictor of the annual relative FVC decline in any group. The incidence of acute exacerbations did not differ significantly between groups. CONCLUSIONS: While baseline NLR did not independently predict the annual relative FVC decline, it was identified as a significant independent predictor of survival time in patients with ILD, particularly those with IPF, following the initiation of nintedanib.
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.

Haruka Nakatani, Hayato Kawachi, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Kenji Morimoto, Koichi Takayama

Anticancer research 46(5) 2789-2806 2026年5月

BACKGROUND/AIM: Cancer cachexia, characterized by weight loss and systemic inflammation, has been associated with poor prognosis in non-small cell lung cancer (NSCLC). However, its impact on treatment outcomes in tumors with mutant epidermal growth factor receptor (EGFR) remains unclear. This multicenter retrospective cohort study evaluated the impact of cancer cachexia on treatment selection after the development of resistance to EGFR tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: This study included 439 patients with advanced EGFR-mutant NSCLC who received chemotherapy (n=304) or immune checkpoint inhibitors (ICIs) combined with chemotherapy (n=135) after EGFR-TKI failure. Cancer cachexia was diagnosed based on specific weight loss criteria and laboratory data. Propensity score matching was performed to adjust for baseline differences, and survival outcomes were compared. RESULTS: Overall, significant differences in treatment outcomes were observed between the groups. In the chemotherapy group, cancer cachexia was an independent predictor of overall survival (hazard ratio=1.53; p=0.004), whereas it was not associated with survival in the ICIs/chemotherapy group. Among patients with cachexia, overall survival was significantly longer with ICIs/chemotherapy than with chemotherapy alone (13.8 vs. 11.2 months; p=0.049). CONCLUSION: Although no significant survival difference was found between chemotherapy and ICIs/chemotherapy in the overall population, ICIs/chemotherapy conferred a survival benefit to patients with cancer cachexia. These findings suggest that the presence of cachexia may serve as a potential biomarker for treatment selection in EGFR-TKI-resistant, EGFR-mutant NSCLC.
Diagnostic and decision-making disparities in precision oncology in thoracic malignancies with interstitial pneumonia: A real-world cohort study

Yutaro Kimura, Naozumi Hashimoto, Toshikazu Watanabe, Yasuhiro Goto, Tomoya Horiguchi, Tomohide Souma, Shotaro Okachi, Yuko Oya, Sumito Isogai, Masashi Kondo, Kazuyoshi Imaizumi

RESPIRATORY INVESTIGATION 64(3) 2026年5月
Navigational Bronchoscopy Training With Spatial Computing: A Simulation-Based Feasibility Report Using Apple Vision Pro

Shotaro Okachi, Takuma Ina, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi

SURGICAL INNOVATION 2026年4月10日
Retrospective study for clinical biomarkers to guide post-EGFR-TKI treatment strategies in EGFR-mutant NSCLC

Tadaaki Yamada, Kenji Morimoto, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Tae Hata, Koji Mikami, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Koichi Takayama

CANCER RESEARCH 86(7) 2026年4月3日
AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers

Masaki Ishida, Tadaaki Yamada, Yuki Katayama, Hayato Kawachi, Ryo Sawada, Ryota Nakamura, Soichi Hirai, Yohei Matsui, Kenji Morimoto, Keisuke Onoi, Aosa Nakamura-Sasada, Mano Horinaka, Toshiyuki Sakai, Tomoki Sakakida, Toshifumi Doi, Kazuo Yasumoto, Yasuhiro Goto, Naoki Furuya, Hirokazu Taniguchi, Hirokazu Ogino, Nakano Takayuki, Yusuke Chihara, Koji Fukuda, Hiroaki Taniguchi, Hisanori Uehara, Seiji Yano, Shinsaku Tokuda, Koichi Takayama

NPJ PRECISION ONCOLOGY 10(1) 2026年4月2日
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Takeo Ogawa, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE 17(2) 2026年4月
Comparison of biomechanical assessment between upright and supine inspiratory-expiratory area-detector CT in progressive pulmonary fibrosis

Yoshiharu Ohno, Kota Aoyagi, Yoshiyuki Ozawa, Masahiko Nomura, Hirona Kimata, Yuya Ito, Kenji Fujii, Takahiro Ueda, Junichiro Araoka, Naruomi Akino, Takeshi Yoshikawa, Daisuke Takenaka, Masahiko Endo, Yasushi Hoshikawa, Hidekata Yasuoka, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi

EUROPEAN RADIOLOGY EXPERIMENTAL 10(1) 2026年3月31日
Initial Experience with Three-Dimensional Holographic Virtual Bronchoscopy Using Mixed Reality for Peripheral Pulmonary Lesions: A Retrospective Feasibility Study

Takuma Ina, Shotaro Okachi, Shoko Kamenosono, Shin Hasegawa, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Yasuhiro Hida, Maki Sugimoto, Michitaka Fujiwara, Kazuyoshi Imaizumi

RESPIRATION 2026年3月13日
Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial.

Takenao Koseki, Masashi Kondo, Hidetsugu Fujigaki, Kayoko Kikuchi, Yuko Oya, Hiroshi Kato, Tomohiro Mizuno, Naotake Tsuboi, Kenji Kawada, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi, Akiko Kada, Hikaru Yabuuchi, Kuniaki Saito, Hideyuki Saya

JMIR research protocols 15 e87907 2026年2月12日
PD-L1発現50%未満高齢者非扁平上皮非小細胞肺がんに対するペムブロリズマブ+ペメトレキセド療法の多施設共同第II相試験:CJLSG1901試験

後藤康洋, 小暮啓人, 橋本大哉, 池田慧, 原田敏之, 日野葵, 三浦理, 藤原慶一, 片上信之, 久保田馨, 村田直彦, 森雅秀, 安部崇, 山本信之, 坂英雄, 近藤征史

日本臨床腫瘍学会学術集会(CD-ROM) 46 101094-101094 2026年1月2日
BRAF V600E-mutant squamous cell carcinoma of the lung in patients with a history of papillary thyroid carcinoma: A three-case series

Naozumi Hashimoto, Ryoma Moriya, Ken Akao, Hisashi Kako, Yasuhiro Goto, Tomohide Souma, Yuko Oya, Yuka Kondo, Tetsuya Tsukamoto, Sumito Isogai, Masashi Kondo, Kazuyoshi Imaizumi

RESPIRATORY INVESTIGATION 64(1) 2026年1月
Antibiotics as a negative factor for Chemoimmunotherapy for non-small cell lung cancer with low PD-L1 expression

Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Takashi Kijima, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Koichi Takayama

CANCER SCIENCE 117 325-325 2026年1月
間質性肺疾患の栄養治療間質性肺疾患の包括的管理における運動療法と栄養療法の役割

後藤康洋

臨床栄養 148(2) 212-217 2026年
High diagnostic yield and treatment impact of bronchoscopy in elderly lung cancer patients (≥ 80 years): A single-center retrospective study

Shingo Maeda, Takuma Ina, Atsuhiko Ota, Masaaki Matsunaga, Tomoya Horiguchi, Aki Ikeda, Ryoma Moriya, Takaya Sato, Chiaki Sawada, Yuko Oya, Shotaro Okachi, Yasuhiro Goto, Sumito Isogai, Naozumi Hashimoto, Masashi Kondo, Kazuyoshi Imaizumi

Respiratory Investigation 64(1) 101335-101335 2026年1月
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Yasuhiro Goto, Sayaka Uda, Akira Nakao, Shinsuke Shiotsu, Yuji Kukida, Keiko Tanimura, Akifumi Miyamoto, Yuki Imasato, Asuka Okada, Isao Hasegawa, Koji Date, Yohei Matsui, Shoki Morito, Noeru Inoguchi, Shuji Osugi, Hayato Kawachi, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Tomohiro Handa, Koichi Takayama

Scientific reports 16(1) 3947-3947 2025年12月27日
Development of a centralized progress management system using lean thinking and efforts to improve operations

Seiji Yahata, Isao Tanaka, Masami Takeuchi, Yasuhiro Goto, Isao Shiina, Satoshi Nakayama, Kazuo Shimura

BMC HEALTH SERVICES RESEARCH 25(1) 2025年12月24日
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Takashi Kijima, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Shimose, Koichi Takayama

Oncoimmunology 14(1) 2442116-2442116 2025年12月
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.

Yusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Masaki Ishida, Takashi Kijima, Koichi Takayama

Translational lung cancer research 14(11) 4733-4745 2025年11月30日
PD-L1<50%の高齢者非扁平上皮非小細胞肺癌に対するペムブロリズマブ+ペメトレキセド療法の肺臓炎の検討

中谷有貴, 小暮啓人, 橋本大哉, 後藤康洋, 山田忠明, 木村智樹, 三浦理, 安井裕智, 山本信之, 坂英雄, 近藤征史

肺癌 65(5) 430-430 2025年11月
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

Daiki Murata, Koichi Azuma, Kenta Murotani, Kazuhiro Ito, Takashi Nomizo, Kazuhiko Yamada, Tatsuya Imabayashi, Kentaro Iwanaga, Kenji Chibana, Takayo Ota, Yuuya Nishii, Akira Nakao, Asuka Okada, Kosuke Hamai, Keiko Tanimura, Kohei Yoshimine, Yosuke Tamura, Ryuichiro Takaki, Yasuhiro Goto, Makoto Hibino, Tomohiro Oba, Toshiyuki Sumi, Hiroyasu Kaneda, Naoya Nishioka, Tadaaki Yamada, Koichi Takayama

LUNG CANCER 209 2025年11月
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.

Aosa Sasada, Hayato Kawachi, Tadaaki Yamada, Tae Hata, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Asuka Okada, Yusuke Chihara, Takashi Kijima, Koichi Takayama

Anticancer research 45(11) 5045-5057 2025年11月
アスピリン負荷試験の副反応出現に長時間を要したN-ERDの1例

高橋秀昂, 渡邊俊和, 相馬智英, 堀口智也, 岡村拓哉, 後藤康洋, 磯谷澄都, 橋本直純, 今泉和良

アレルギー 74(抄録号) s337-s337 2025年9月
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.

Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto, Hiroshi Mukae

Lung cancer (Amsterdam, Netherlands) 207 108709-108709 2025年8月12日
Influence of renal function on the clinical efficacy of carboplatin plus pemetrexed in patients with non-small cell lung cancer

Kazuki Komeda, Tetsunari Hase, Toru Hara, Tomoki Kimura, Eiji Kojima, Takashi Abe, Yoshitsugu Horio, Yasuhiro Goto, Futoshi Ushijima, Shohei Watanabe, Yuki Yamada, Tomoya Shimokata, Tetsuya Oguri, Masashi Yamamoto, Kiyoshi Yanagisawa, Masahiko Ando, Masashi Kondo, Yoshinori Hasegawa, Makoto Ishii

NAGOYA JOURNAL OF MEDICAL SCIENCE 87(3) 483-497 2025年8月
Advanced machine learning models for prediction of readmission and mortality risks in patients with chronic obstructive pulmonary disease using routine clinical data.

Yasuhiro Goto, Daisuke Niwa, Shuhei Shibata, Ryoma Nishimoto, Masami Miyata, Takashi Kanno, Toshiyuki Washizawa, Masashi Kondo, Kazuyoshi Imaizumi

Fujita medical journal 11(3) 121-128 2025年8月

OBJECTIVES: To develop a comprehensive machine learning model incorporating various clinical factors, including frailty and comorbidities, to predict 30-day readmission and mortality risk in patients with chronic obstructive pulmonary disease (COPD). METHODS: This retrospective cohort study used electronic health records (EHR) from Fujita Health University Hospital (2004-2019) for 1294 patients with COPD and 3499 hospitalization or death events. The EHR contained longitudinal patient data (demographics, diagnoses, test results, clinical records). We developed two eXtreme Gradient Boosting models, the comprehensive Top64 and practical 11-feature models. We compared these with the Comorbidity, Obstruction, Dyspnea, and Previous Exacerbations index (CODEX) model, a widely used tool for predicting hospital readmission or death in patients with COPD. The area under the receiver operating characteristic curve (AUC) with 95% confidence interval (CI), sensitivity, and specificity were used to evaluate the model performance. RESULTS: The Top64 (AUC: 0.769, 95% CI: 0.747-0.791) and practical 11-feature (AUC: 0.746, 95% CI: 0.730-0.762) models performed better than the CODEX model (AUC: 0.587, 95% CI: 0.563-0.611). The Top64 model showed 0.978 sensitivity and 0.341 specificity, and the practical 11-feature model achieved 0.955 sensitivity and 0.361 specificity. The calibration curves showed good agreement between the observed and predicted results for both models. CONCLUSIONS: A machine learning approach based on clinical data readily available from the EHR performed better than existing models in predicting 30-day readmission and mortality risks in patients with COPD. A comprehensive risk prediction tool may enhance individualized care strategies and improve patient outcomes in COPD management.
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Koichi Takayama

International journal of clinical oncology 30(10) 1963-1971 2025年7月22日
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.

Tae Hata, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Hayato Kawachi, Kenji Morimoto, Koichi Takayama

Clinical lung cancer 26(8) e639-e648 2025年7月22日
Myocardial injury in Duchenne muscular dystrophy: assessment via cardiac magnetic resonance intra-voxel incoherent motion.

Atsushi Yamamoto, Michinobu Nagao, Keiko Ishigaki, Minobu Shichiji, Yuki Kihara, Akiko Sakai, Yuichiro Minami, Yasuhiro Goto, Masami Yoneyama, Shuji Sakai, Junichi Yamaguchi

Heart and vessels 2025年7月21日

Duchenne muscular dystrophy (DMD) is a progressive myopathy caused by a mutation in the dystrophin gene. Cardiac disease is currently the leading cause of death in patients with DMD; thus, early diagnosis and management of cardiomyopathy are essential. Intra-voxel incoherent motion (IVIM) analysis provides quantitative values from diffusion-weighted imaging (DWI) and may serve as a novel index for evaluating myocardial properties in DMD. We conducted IVIM analysis in patients with DMD and compared their results with those of healthy volunteers to confirm that IVIM analysis can detect myocardial damage more effectively than conventional imaging methods. Patients with DMD who underwent cardiac magnetic resonance IVIM were enrolled. D and F values were measured using DWI of the left ventricle. Six healthy volunteers served as the control group. Twelve male patients with DMD were enrolled (median age, 14 years). Creatinine kinase levels were elevated, brain natriuretic peptide values remained within the normal range, and troponin T levels were only mildly elevated. The D value in patients with DMD was significantly higher than that in healthy volunteers, indicating increased diffusion in the myocardium (2.59 vs. 1.85, p = 0.0057); however, the F value was comparable between the two groups (0.62 vs. 0.61, p = 0.60). The D and F values from IVIM analysis provided a more detailed reflection of myocardial properties. Myocardial diffusion in patients with DMD was elevated compared with that in healthy volunteers.
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Makoto Hibino, Asuka Okada, Yusuke Chihara, Hayato Kawachi, Takashi Kijima, Koichi Takayama

Cancer research communications 5(7) 1203-1214 2025年7月1日
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study.

Ryo Sawada, Tadaaki Yamada, Yasuhiro Goto, Yoshiki Negi, Akira Nakao, Akihiro Yoshimura, Naoki Furuya, Tomohiro Oba, Makoto Hibino, Haruka Nakatani, Hirokazu Taniguchi, Aya Ohtsubo, Satoshi Watanabe, Takahiro Yamada, Yusuke Chihara, Takashi Kijima, Koichi Takayama

Translational lung cancer research 14(6) 1986-2000 2025年6月30日
Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834)

Kyoji Tsurumi, Satoru Miura, Toshihiro Misumi, Hiroshige Yoshioka, Takaaki Tokito, Yuki Sato, Kazumi Nishino, Naoki Furuya, Takayasu Kurata, Terufumi Kato, Hidehito Horinouchi, Yuichi Takiguchi, Yasuhiro Goto, Kentaro Tanaka, Masahide Mori, Satoshi Ikeda, Eiki Ichihara, Hiroshi Tanaka, Hiroaki Okamoto

JOURNAL OF CLINICAL ONCOLOGY 43(16_SUPPL) 2025年6月1日
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.

Hayato Kawachi, Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Makoto Hibino, Asuka Okada, Yusuke Chihara, Takashi Kijima, Koichi Takayama

Translational lung cancer research 14(5) 1558-1568 2025年5月30日
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.

Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Hayato Kawachi, Koichi Takayama

Targeted oncology 20(3) 531-541 2025年5月
Preoperative Immersive Virtual Reality Planning and Simulation of Bronchoscopic Lung Volume Reduction Using Endobronchial Valves.

Shotaro Okachi, Hideaki Takahashi, Hisashi Kako, Takuma Ina, Tomoya Horiguchi, Yasuhiro Goto, Yasushi Matsuda, Sumito Isogai, Naozumi Hashimoto, Michitaka Fujiwara, Kazuyoshi Imaizumi

Respirology case reports 13(5) e70157 2025年5月
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto, Tae Hata, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Asuka Okada, Makoto Hibino, Yusuke Chihara, Takashi Kijima, Koichi Takayama

Translational lung cancer research 14(4) 1185-1196 2025年4月30日
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi, Hiroshige Yoshioka, Takaaki Tokito, Tatsuro Fukuhara, Yuki Sato, Yoshimasa Shiraishi, Katsuhiko Naoki, Hiroaki Akamatsu, Ou Yamaguchi, Toshihide Yokoyama, Shoichi Kuyama, Kazumi Nishino, Naoki Furuya, Takayasu Kurata, Terufumi Kato, Satoshi Ikeda, Hidehito Horinouchi, Eiki Ichihara, Masahide Mori, Yuichi Takiguchi, Kentaro Tanaka, Yasuhiro Goto, Hiroaki Okamoto

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 43(18) JCO2402007-2058 2025年4月16日
Clinical Applicability of Three-Dimensional Holographic Virtual Bronchoscopy with Mixed Reality.

Shotaro Okachi, Maki Sugimoto, Takuma Ina, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Michitaka Fujiwara, Kazuyoshi Imaizumi

Annals of the American Thoracic Society 22(4) 609-611 2025年4月
PD-L1低発現の間質性肺炎合併非小細胞肺癌の治療選択 Chemo-IOとChemoの比較

永田裕太郎, 笹田碧沙, 山田忠明, 畑妙, 後藤康洋, 天野明彦, 木島貴志, 渡部聡, 古屋直樹, 大場智広, 中尾明, 谷村恵子, 谷口寛和, 吉村彰紘, 福井朋也, 村田大樹, 解良恭一, 高山浩一

日本呼吸器学会誌 14(増刊) 312-312 2025年3月
PD-L1低発現の高齢者進行期NSCLCに対する複合免疫療法の有効性

谷口寛和, 河内勇人, 畑妙, 山田忠明, 後藤康洋, 天野明彦, 木島貴志, 渡部聡, 古屋直樹, 大場智広, 生駒龍興, 中尾明, 谷村恵子, 吉村彰紘, 福井朋也, 村田大樹, 解良恭一, 高山浩一

日本呼吸器学会誌 14(増刊) 313-313 2025年3月
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.

Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Koichi Takayama

Lung cancer (Amsterdam, Netherlands) 201 108447-108447 2025年3月
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Makoto Hibino, Asuka Okada, Yusuke Chihara, Hayato Kawachi, Takashi Kijima, Koichi Takayama

Lung cancer (Amsterdam, Netherlands) 200 108104-108104 2025年2月
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Makoto Hibino, Asuka Okada, Yusuke Chihara, Hayato Kawachi, Takashi Kijima, Koichi Takayama

Clinical lung cancer 26(3) e190-e198.e4 2025年1月4日
Pleural dissemination of epithelioid hemangioendothelioma diagnosed using semi-rigid thoracoscopic pleural cryobiopsy.

Tomoya Horiguchi, Shin Hasegawa, Yoshiko Shigeyasu, Nanami Kiryu, Maki Ota, Shotaro Okachi, Yasuhiro Goto, Naozumi Hashimoto, Kenji Kawada, Kazuyoshi Imaizumi

Respiratory medicine case reports 57 102276-102276 2025年
[Hemosuccus pancreaticus with a pancreatic metastasis from colorectal cancer receiving edoxaban:a case report].

Shiro Nakae, Kosuke Minaga, Tomohiro Kawamura, Tomohiko Matsuda, Yasuhiro Goto, Shiho Sakurai, Tomo Nakagawa, JeonUk Lee, Taihei Iwaya, Takuya Yamaguchi

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 122(4) 297-304 2025年

A 60-year-old male patient with metastasis from sigmoid colon cancer in the pancreatic uncinate process who received chemotherapy was treated with edoxaban (EDO) because of deep vein thrombosis. The pancreatic metastasis appeared to shrink, but the patient had repeated acute pancreatitis. An upper gastrointestinal endoscopy was performed to determine the cause. Bleeding from the major papilla and the minor papilla was detected, and he was diagnosed with hemosuccus pancreaticus. Pancreatic duct stenting was conducted from the minor papilla. The pancreatitis was then improved and the EDO dosage was reduced. The pancreatic duct stent fell off during the course. Hemosuccus pancreaticus has not relapsed after 1 year from the dropout of the stent. EDO was considered responsible for hemosuccus pancreaticus.
Blood DNA virome associates with autoimmune diseases and COVID-19.

Noah Sasa, Shohei Kojima, Rie Koide, Takanori Hasegawa, Ho Namkoong, Tomomitsu Hirota, Rei Watanabe, Yuumi Nakamura, Eri Oguro-Igashira, Kotaro Ogawa, Tomohiro Yata, Kyuto Sonehara, Kenichi Yamamoto, Toshihiro Kishikawa, Saori Sakaue, Ryuya Edahiro, Yuya Shirai, Yuichi Maeda, Takuro Nii, Shotaro Chubachi, Hiromu Tanaka, Haruka Yabukami, Akari Suzuki, Kimiko Nakajima, Noriko Arase, Takashi Okamoto, Rika Nishikawa, Shinichi Namba, Tatsuhiko Naito, Ippei Miyagawa, Hiroaki Tanaka, Masanobu Ueno, Yosuke Ishitsuka, Junichi Furuta, Kayo Kunimoto, Ikko Kajihara, Satoshi Fukushima, Hideaki Miyachi, Hiroyuki Matsue, Masahiro Kamata, Mami Momose, Toshinori Bito, Hiroshi Nagai, Tetsuya Ikeda, Tatsuya Horikawa, Atsuko Adachi, Tsukasa Matsubara, Kyoko Ikumi, Emi Nishida, Ikuma Nakagawa, Mayu Yagita-Sakamaki, Maiko Yoshimura, Shiro Ohshima, Makoto Kinoshita, Satoru Ito, Toru Arai, Masaki Hirose, Yoshinori Tanino, Takefumi Nikaido, Toshio Ichiwata, Shinya Ohkouchi, Taizou Hirano, Toshinori Takada, Ryushi Tazawa, Konosuke Morimoto, Masahiro Takaki, Satoshi Konno, Masaru Suzuki, Keisuke Tomii, Atsushi Nakagawa, Tomohiro Handa, Kiminobu Tanizawa, Haruyuki Ishii, Manabu Ishida, Toshiyuki Kato, Naoya Takeda, Koshi Yokomura, Takashi Matsui, Akifumi Uchida, Hiromasa Inoue, Kazuyoshi Imaizumi, Yasuhiro Goto, Hiroshi Kida, Tomoyuki Fujisawa, Takafumi Suda, Takashi Yamada, Yasuomi Satake, Hidenori Ibata, Mika Saigusa, Toshihiro Shirai, Nobuyuki Hizawa, Koh Nakata, Shinichi Imafuku, Yayoi Tada, Yoshihide Asano, Shinichi Sato, Chikako Nishigori, Masatoshi Jinnin, Hironobu Ihn, Akihiko Asahina, Hidehisa Saeki, Tatsuyoshi Kawamura, Shinji Shimada, Ichiro Katayama, Hannah M Poisner, Taralynn M Mack, Alexander G Bick, Koichiro Higasa, Tatsusada Okuno, Hideki Mochizuki, Makoto Ishii, Ryuji Koike, Akinori Kimura, Emiko Noguchi, Shigetoshi Sano, Hidenori Inohara, Manabu Fujimoto, Yoshikazu Inoue, Etsuro Yamaguchi, Seishi Ogawa, Takanori Kanai, Akimichi Morita, Fumihiko Matsuda, Mayumi Tamari, Atsushi Kumanogoh, Yoshiya Tanaka, Koichiro Ohmura, Koichi Fukunaga, Seiya Imoto, Satoru Miyano, Nicholas F Parrish, Yukinori Okada

Nature genetics 57(1) 65-79 2025年1月
Safety and efficacy of transbronchial cryobiopsy for elderly lung cancer patients.

Kumiko Yamatsuta, Shotaro Okachi, Shin Hasegawa, Maki Ota, Hisashi Kako, Takuma Ina, Tomoya Horiguchi, Yuko Oya, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi

BMC pulmonary medicine 24(1) 632-632 2024年12月26日

MISC

484

胸腔鏡下クライオ生検でも診断に難渋したIgG4関連疾患による胸膜炎の1例

桐生七海, 池田安紀, 岡地祥太郎, 長谷川信, 渡邊俊和, 堀口智也, 大矢由子, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

気管支学 48(2) 153-153 2026年3月
ITツールを用いた気管支鏡検査のインフォームドコンセント支援効果の検証

後藤康洋, 堀口智也, 桐生七海, 長谷川新, 外山陽子, 大矢由子, 岡地祥太郎, 長谷哲成, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

気管支学 48(2) 153-153 2026年3月
著明な胸腔鏡所見を呈した濾胞性リンパ腫の1例

亀之園翔子, 高橋秀昂, 渡邊俊和, 大矢由子, 堀口智也, 後藤康洋, 橋本直純, 近藤征史, 今泉和良

肺癌 65(7) 1090-1090 2025年12月
C-CATデータを利用したdriver陰性NSCLCにおける年齢別の遺伝子変異の検討

森谷遼馬, 大矢由子, 加古寿志, 岡地祥太郎, 堀口智也, 後藤康洋, 磯谷澄都, 須藤保, 橋本直純, 近藤征史, 今泉和良

肺癌 65(5) 516-516 2025年11月
免疫チェックポイント阻害薬関連サイトカイン放出症候群の臨床的特徴

森谷遼馬, 大矢由子, 桐生七海, 加古寿志, 石井友里加, 伊奈拓摩, 岡地祥太郎, 堀口智也, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

肺癌 65(5) 574-574 2025年11月

もっとみる

書籍等出版物

JSPENコンセンサスブック2 肺疾患／肝疾患／腎疾患

(担当:分担執筆)

2023年5月 (ISBN: 9784260052399)
【Rheumatological emergencyの診断と治療】肺胞出血

後藤康洋, 今泉和良 (担当:分担執筆, 範囲:149-153)

リウマチ科 2019年8月
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma

後藤, 康洋

[s.n.] 2010年
COPD連携手帳

後藤康洋 (担当:分担執筆, 範囲:栄養療法、呼吸・運動療法)

愛知県COPDネットワーク

講演・口頭発表等

457

IgG4関連疾患による気道病変を認めた1例

池田安紀, 岡地祥太郎, 大矢由子, 佐藤孝哉, 堀口智也, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

気管支学 2024年
EBUS-TBNA-MFB(Mini Forceps Biopsy)における超音波気管支鏡の機種による相違

赤尾謙, 伊奈拓摩, 堀口智也, 岡地祥太郎, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

気管支学 2024年
縦隔病変に対するEBUS-MFBの有用性の検討

伊奈拓摩, 澤田千晶, 廣地真理子, 石井友里加, 堀口智也, 丹羽義和, 岡村拓哉, 魚津桜子, 岡地祥太郎, 後藤康洋, 橋本直純, 近藤征史, 今泉和良

気管支学 2024年
気管支鏡直視下生検におけるクライオ生検は検査後感染症を少なくするか

相馬智英, 重康善子, 池田安紀, 堀口智也, 岡地祥太郎, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

気管支学 2024年
局所麻酔下胸腔鏡クライオ生検は胸膜中皮腫診断における標準的手技となり得るか

堀口智也, 重康善子, 長谷川新, 澤田千晶, 岡地祥太郎, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良

気管支学 2024年

もっとみる

所属学協会

もっとみる

共同研究・競争的資金等の研究課題

簡易スパイロメーターによるCOPDスクリーニングの有用性

一般財団法人愛知健康増進財団医学研究・健康増進活動等助成 2020年4月 - 2021年3月

後藤康洋

教育方法・教育実践に関する発表、講演等

件名

第一回研修医のための呼吸器セミナー

開始年月日

2018/02/03

終了年月日

2018/02/03

概要

東海4県の医学系大学が集まり、初期研修医向けの呼吸器セミナーを開催
件名

第二回研修医のための呼吸器セミナー(主幹)

開始年月日

2019/02/02

終了年月日

2019/02/02

概要

呼吸器学会東海支部主催で初期研修医向けの呼吸器セミナーを開催（当大学が主幹で主催した）

一覧へ戻る

後藤 康洋

基本情報

研究分野

経歴

学歴

委員歴

論文

MISC

書籍等出版物

講演・口頭発表等

所属学協会

共同研究・競争的資金等の研究課題

教育方法・教育実践に関する発表、講演等

後藤康洋